VITAL phase 2 study: Upfront 5‐fluorouracil, mitomycin‐C, panitumumab and radiotherapy treatment in nonmetastatic squamous cell carcinomas of the anal canal (GEMCAD 09‐02)

Overview of attention for article published in Cancer Medicine, December 2019

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
Good Attention Score compared to outputs of the same age (79th percentile)
High Attention Score compared to outputs of the same age and source (88th percentile)

Mentioned by

blogs: 1 blog
twitter: 3 X users

facebook: 1 Facebook page

Citations

dimensions_citation: 11 Dimensions

Readers on

mendeley: 26 Mendeley

Summary Blogs X Facebook Dimensions citations

So far, Altmetric has seen 4 X posts from 3 X users, with an upper bound of 8,523 followers.

#PublicaSalutIB Fase 2 de l'estudi VITAL https://t.co/Xrwf6yGBiJ @SonLlatzer https://t.co/uQIZF3K8mq https://t.co/vWss0DbgNX

17 Mar 2020

Reply Repost Favourite

#PublicaSalutiB Fase 2 del estudio VITAL https://t.co/K1YrPImPA5 @SonLlatzer https://t.co/mBXChEidbK https://t.co/cgyZcc3mRy

11 Mar 2020

Reply Repost Favourite

#PublicaSalutIB Fase 2 de l'estudi VITAL https://t.co/XwNSWW3FHm @SonLlatzer https://t.co/mBXChEidbK https://t.co/C4kyf71F37

11 Mar 2020

Reply Repost Favourite

VITAL phase 2 study: Upfront 5-fluorouracil, mitomycin-C, panitumumab and radiotherapy treatment in nonmetastatic squamous cell carcinomas of the anal canal (GEMCAD 09-02). https://t.co/pQvod6GTCO h/t @NCBI #RadOnc #PubMed

19 Dec 2019

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.